Nav: Home

Why are migraine patients skipping effective behavioral treatments?

June 05, 2018

Effective behavioral treatments for migraine are being eschewed by a significant number of sufferers, according to a new study led by headache researchers at NYU School of Medicine.

Researchers found that about half of migraine patients who were referred by a headache center for specific behavioral treatment did not follow through with therapy. This occurred despite the fact that these treatments are considered first-line, safe and effective treatments by medical guidelines.

Those who were referred but did not seek treatment most commonly cited lack of time, cost concerns, and skepticism the treatments will work, according to the new study published in the June 5 issue of Pain Medicine.

An estimated 36 million Americans live with migraines, which are recurrent attacks that cause moderate to severe throbbing pain, and are often accompanied by nausea and/or vomiting and sensitivity to light and sound. Migraines are the sixth most disabling condition worldwide, often resulting in missed work and high utilization of health care services.

Previous research shows that behavioral migraine treatments, including cognitive behavioral therapy (CBT), stress management, relaxation techniques, and biofeedback -- learning to reduce muscle tension with help of a monitoring device -- may reduce symptoms by 50 percent or more. Behavioral treatments can be less costly than medications and have enduring benefits for migraine reduction, according to the researchers, which led them to explore why many patients were not following through on treatment.

"Migraines can be debilitating, so it stands to reason that many patients would want to access a treatment that reduces symptoms by half," says Mia Minen, MD, MPH, an assistant professor of Neurology and Population Health at NYU School of Medicine, and director of research for NYU Langone's Headache Division. "However, our research shows this is far from the case."

Researchers prospectively tracked 234 patients with migraines who presented to an academic headache center, and referred 69 of them for behavioral treatment with a therapist trained in migraines. Fifty-three patients who completed a follow-up interview within three months of their initial appointment were included in the analysis.

Of the patients referred for behavioral treatment, only 30 (56.6 percent) made an appointment. Researchers found no differences between those who started therapy and those who didn't when looking at age, gender, years of suffering from migraines and overall utilization of health care services. However, they did find a significant difference: people who had previously seen a psychologist were more likely to initiate therapy.

Of the patients who did not initiate behavioral treatment, half cited time limitations as a barrier to adherence. In addition to time, patients did not initiate for reasons including cost - since some insurance plans don't cover -- skepticism that it would work, contentment with their current treatment plan, and satisfaction that their headaches were already improving.

Dr. Minen and her colleagues say that more research is needed to develop new methods to overcome these barriers. They add that given concerns about migraine and stigma, research on whether stigma plays a role in limiting patients' abilities to access behavioral treatment should also be explored.

"As providers, we need to develop new ways to present evidence-based behavioral treatments to patients in a similar manner in which pharmacologic therapies are presented, with attention to how behavioral treatments can be part of a larger patient-centered care plan," she said.

Many drugs on the market that reduce or control migraine symptoms often can cause other negative symptoms, according to the authors. A new class of monoclonal antibody medications for migraine, called CGRP inhibitors, have generated excitement among the migraine community as a new treatment option. While these medications have been shown to result in a 50-percent reduction in half of those using them, they are not a cure for migraine; thus, there is a need for creating evidence-based scalable, accessible behavioral treatments, according to the authors.

Other available treatments for migraine include medications, vitamin supplements, and botulinum toxin injections.
This research received no grant funding support; Dr. Minen is a recipient of the American Academy of Neurology-American Brain Foundation Practice Research Training Fellowship, which provides salary support to conduct research.

In addition to Dr. Minen, researchers at NYU School of Medicine included Sarah Azarchi, BS, Rachel Sobolev, BA, Amanda Shallcross, ND, MPH, Audrey Halpern, MD, Thomas Berk, MD, and Naomi M. Simon, MD. Other researchers included Scott Powers, PhD, Richard B. Lipton, MD, and senior author Elizabeth Seng, PhD.

NYU Langone Health / NYU School of Medicine

Related Migraine Articles:

Both too much, too little weight tied to migraine
Both obesity and being underweight are associated with an increased risk for migraine, according to a meta-analysis published in the April 12, 2017, online issue of Neurology®, the medical journal of the American Academy of Neurology.
Examining whether migraine is associated with cervical artery dissection
A new study published online by JAMA Neurology examines whether a history of migraine is associated with cervical artery dissection (CEAD), a frequent cause of ischemic (blood vessel-related) stroke in young and middle-age adults, although the causes leading to vessel damage are unclear.
Migraine associated with higher risk of stroke after surgery
Surgical patients with a history of migraines have a greater risk of stroke and readmission to hospital, finds a study published by The BMJ today.
Migraine as a risk marker for stroke and heart attack
A team of researchers led by Professor Tobias Kurth, Head of the Institute of Public Health at Charité -- Universitätsmedizin Berlin, has now been able to establish the following: female migraine patients have a higher risk of stroke or heart attacks than women without migraine.
Are drops in estrogen levels more rapid in women with migraine?
Researchers have long known that sex hormones such as estrogen play a role in migraine.
Migraine drugs underused
New research shows that more migraines could be safely treated with drugs that are known to constrict blood vessels.
Managing migraine during pregnancy and lactation
According to doctors at Wake Forest Baptist Medical Center, medications and treatments long considered safe to treat pregnant women with migraines may not be.
Children who are emotionally abused may be more likely to experience migraine as adults
Children who are emotionally abused may be more likely to experience migraines as young adults, according to a preliminary study released today that will be presented at the American Academy of Neurology's 68th Annual Meeting in Vancouver, Canada, April 15 to 21, 2016.
Migraine triggers may all act through a common pathway
Migraines can be triggered by a variety of factors, including stress, sleep disruption, noise, odors, and diet.
A new marker for migraine?
Researchers may have discovered a new marker found in the blood for episodic migraine, according to a study published in the Sept.

Related Migraine Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Changing The World
What does it take to change the world for the better? This hour, TED speakers explore ideas on activism—what motivates it, why it matters, and how each of us can make a difference. Guests include civil rights activist Ruby Sales, labor leader and civil rights activist Dolores Huerta, author Jeremy Heimans, "craftivist" Sarah Corbett, and designer and futurist Angela Oguntala.
Now Playing: Science for the People

#521 The Curious Life of Krill
Krill may be one of the most abundant forms of life on our planet... but it turns out we don't know that much about them. For a create that underpins a massive ocean ecosystem and lives in our oceans in massive numbers, they're surprisingly difficult to study. We sit down and shine some light on these underappreciated crustaceans with Stephen Nicol, Adjunct Professor at the University of Tasmania, Scientific Advisor to the Association of Responsible Krill Harvesting Companies, and author of the book "The Curious Life of Krill: A Conservation Story from the Bottom of the World".